Georgia Governor Brian Kemp has signed Senate Bill 220 (SB 220), officially known as the “Putting Georgia’s Patients First Act,” into law. This legislation significantly expands medical cannabis access for registered patients across the state, introducing changes to potency limits, qualifying conditions, and product forms.
The new law, signed on the final day for legislative vetoes, redefines the state’s approach to medical cannabis, moving beyond the previous “low THC oil” designation. Georgia is now the 41st U.S. state to specifically permit cannabis for medical purposes, though recreational use remains prohibited, according to CBS News Atlanta.
Legislative Changes in SB 220
Potency and Possession Revisions
A key provision of the “Putting Georgia’s Patients First Act” is the removal of the prior 5% THC potency cap on medical cannabis products. This cap is replaced by a legal possession limit of 12,000 milligrams of medical cannabis for registered patients, provided the products are kept in labeled pharmaceutical containers. This adjustment allows for a broader range of product types to be sold by dispensaries, including edibles, gummies, and vaporized flower.
Expanded Qualifying Conditions and Product Forms
The legislation broadens the list of medical conditions that qualify patients for medical cannabis. New additions to the registry include lupus, intractable pain, autism, Stage III HIV, severe Alzheimer’s disease, and inflammatory bowel disease. Furthermore, the law removes previous requirements for conditions to be classified as “severe” or “end-stage” for many illnesses. For patients aged 21 and over, vaporization is now an approved delivery method, a change from previous restrictions. Patients with incurable or irreversible conditions are also no longer required to undergo annual certification.
Regulatory Oversight and Industry Implications
Role of the Georgia Access to Medical Cannabis Commission
The Georgia Access to Medical Cannabis Commission has been granted expanded powers under SB 220. Its responsibilities now include studying best practices for medical cannabis, coordinating with state health officials, and overseeing a comprehensive “seed-to-sale” tracking system to monitor all cannabis cultivated and sold within Georgia. Licensees failing to adhere to commission rules may face fines of up to $25,000 for a first offense. The commission is also tasked with conducting public awareness activities regarding the appropriate use of medical cannabis.
Operational and Compliance Requirements
- Facility Proximity: Production facilities must maintain a minimum distance of 3,000 feet from any school or church.
- Out-of-State Cards: Individuals holding an out-of-state registry card may legally possess medical cannabis in Georgia for up to 45 days.
- Card Validity: A Georgia medical cannabis registration card remains valid for five years from its date of issuance.
- Electronic Registration: The law mandates the Department of Public Health to establish rules for electronic registration cards, though the timeline for this transition to digital cards has not yet been specified.
- Medical Claims: Specific details regarding the “reliable scientific evidence” required to support medical claims made by licensees to physicians are also pending further clarification.
Future Implementation and Restrictions
While the law expands access, certain restrictions remain in place. Smoking or burning medical cannabis is explicitly prohibited, although vaporization is permitted for patients over 21. The use of medical cannabis in public places, including with any heating element or electronic device, continues to be unlawful. State officials are required to develop rules for the implementation of ingestion laws by January 1, 2027.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
